Raymond James analyst Martin Auster downgraded BridgeBio Pharma (NASDAQ: BBIO) from Outperform to Market Perform.The analyst comments: “Attruby continues to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades